JMDC (4483) investor relations material

Executive summary

• Achieved robust growth in Q3 FY2025, with consolidated revenue for the nine months ended December 31, 2025, rising 23.2% year-over-year to ¥36,488 million, and operating profit up 37.1% to ¥7,767 million.

• Consolidated EBITDA was ¥9,682 million, a 27.1% increase year-over-year, and profit attributable to owners of parent increased 24.6% to ¥4,811 million.

• Strategic alliance with an EMR provider announced, expected to enhance data infrastructure and value for stakeholders from next fiscal year.

• The dispensing pharmacy support business was classified as discontinued operations following the transfer of NOAH MEDICAL SYSTEM CORPORATION.

• Basic earnings per share rose to ¥73.58 from ¥59.11 year-over-year.

Financial highlights

• Gross profit increased to ¥20,001 million from ¥16,799 million year-over-year.

• Comprehensive income attributable to owners of parent was ¥4,872 million, up from ¥4,571 million.

• Cash and cash equivalents at period end were ¥30,239 million, down ¥1,937 million from March 31, 2025.

• EBITDA margin improved to 27% from 26% in the prior year.

• Operating profit rose 37% to ¥7,767 million, with profit attributable to owners up 28% to ¥4,811 million.

Outlook and guidance

• Full-year revenue forecast for fiscal year ending March 31, 2026, is ¥50,500 million, with operating profit of ¥11,500 million and EBITDA of ¥14,500 million.

• Basic earnings per share for the full year are projected at ¥113.20.

• No revisions to previously announced earnings forecasts.

• Full-year business momentum remains positive, with management focused on meeting guidance.

• Anticipates further growth driven by new data utilization and efficiency improvements.